
In Charlestown, smaller ambitions for big housing development
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
'We don't have a lot of five-acre sites in the city,' Dillon said. 'This is the kind of project that we need.'
Advertisement
There's a lot to like about the site — its proximity to the T, the historic Charlestown neighborhood, and downtown, said Abby Goldenfarb, Trinity's senior vice president. And with five acres comes a chance for some creative landscaping and other community-focused features, such as a public plaza and lawn, athletic fields, and space for arts and early childhood education.
But despite the site's size, it comes with a host of restrictions, Goldenfarb said. Trinity spent nearly a year pushing to shift a state service road that runs immediately behind the site to a spot closer to the nearby Route 1 on-ramp. But after many months of conversations with state transportation officials and Boston Sand & Gravel, which also uses the access road, that idea fell through.
Advertisement
Affordable housing developer Trinity Financial has proposed an 85-foot, 125-unit affordable apartment complex with an urban plaza and lawn for the project's first phase.
ICON Architecture
Trinity's
Cutting the total number of units allows Trinity to pursue wood-frame construction over a podium — a more affordable option than building taller — and also still allowed opportunity for financial support from the city and state.
'We wish we were able to start construction a few years ago,' Goldenfarb said. 'Construction costs have gone up, so we're trying to build the most economically feasible project we can in the first phase, just to start the momentum.'
Related
:
City officials asked Trinity to explore whether they could build affordable condos in the first phase, but the project needed more governmental subsidy than was available, Goldenfarb said. MassHousing's CommonwealthBuilder program, for example, has per-unit funding caps of between $150,000 and $250,000 for units set aside for households making between 70 percent to 120 percent of the area median income.
Advertisement
'The cost differential between what it costs to build a unit and how much subsidy you're able to get for it was just too large to finance,' Goldenfarb said. 'We also didn't want to be in a position where we ... had to sell very, very expensive market-rate units in order to make the affordable units work.'
So Trinity started exploring affordable rental apartments — a property type it has long built — and cut down the total number of units in the first phase.
Trinity Financial executives Kenan Bigby and Abby Goldenfarb at the Austin Street site in 2023.
Lane Turner/Globe Staff
Likely investors for the first phase include low-income housing tax credit investors, who consider Boston an 'extremely attractive' market, Goldenfarb said. She's expecting strong interest, but is aware that Trinity is also competing against property owners selling their buildings at rock-bottom prices.
'A lot of owners are selling buildings at a discount, so we're going to have to work really hard to make a building that investors want to take lease-up risk on and construction risk on,' she said.
Dillon, Boston's housing chief, said the city recognizes the difficult building environment and is working project-by-project to help developers problem solve — whether that's 'value engineering' or allowing them to safely store materials they've stockpiled.
'It is not an easy time for Boston, or most major cities right now, to to continue to advance an affordable housing and income-restricted housing agenda, but we're not going to stop,' Dillon said. 'Boston is committed to increasing our housing stock and ensuring that a very high amount of the housing that we're creating is income-restricted and affordable to our residents.'
Advertisement
Catherine Carlock can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
New Technical White Paper Highlights Five Essential Questions for Life Sciences Companies as Generative AI Grows and Evolves WALTHAM, Mass., June 04, 2025--(BUSINESS WIRE)--Trinity Life Sciences, the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI. GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? "GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact," said Rajeev Rangachari, Chief Technology Officer at Trinity Life Sciences. "Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales." "To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs," added Jonathan Jenkins, Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit View source version on Contacts Media Contact: Michele WlodarczykTrinity Life Sciencesmwlodarczyk@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
4 hours ago
- Associated Press
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 4, 2025-- Trinity Life Sciences , the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI . This press release features multimedia. View the full release here: A technical white paper from Trinity Life Sciences, Technology with a Point of View: Encoding Life Sciences Expertise with AI, discusses the journey to achieving successful transformation with generative AI. (Graphic: Trinity Life Sciences) GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? 'GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact,' said Rajeev Rangachari , Chief Technology Officer at Trinity Life Sciences. 'Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales.' 'To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs,' added Jonathan Jenkins , Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here . About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit . View source version on CONTACT: Media Contact: Michele Wlodarczyk Trinity Life Sciences [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: RESEARCH PROFESSIONAL SERVICES PHARMACEUTICAL DATA MANAGEMENT TECHNOLOGY ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY DATA ANALYTICS SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH SOURCE: Trinity Life Sciences Copyright Business Wire 2025. PUB: 06/04/2025 08:37 AM/DISC: 06/04/2025 08:36 AM


Business Wire
4 hours ago
- Business Wire
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
WALTHAM, Mass.--(BUSINESS WIRE)-- Trinity Life Sciences, the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI. GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? 'GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact,' said Rajeev Rangachari, Chief Technology Officer at Trinity Life Sciences. 'Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales.' 'To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs,' added Jonathan Jenkins, Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit